Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

Bram Verstockt; Nurulamin M. Noor; Urko M. Marigorta; Polychronis Pavlidis; Parakkal Deepak; Ryan C. Ungaro; Claudio Fiocchi; Joana Torres; Michael Scharl

doi:10.1093/ecco-jcc/jjab050

Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

Bram Verstockt
, Nurulamin M. Noor
, Urko M. Marigorta
, Polychronis Pavlidis
, Parakkal Deepak
, Ryan C. Ungaro
, Claudio Fiocchi
, Joana Torres
, Michael Scharl

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.

Original language	English
Pages (from-to)	1431-1442
Number of pages	12
Journal	Journal of Crohn's and Colitis
Volume	15
Issue number	9
DOIs	https://doi.org/10.1093/ecco-jcc/jjab050
State	Published - 1 Sep 2021

Keywords

Precision medicine
disease outcome
disease prognosis
inflammatory bowel diseases
personalised medicine
response to therapy

Access to Document

10.1093/ecco-jcc/jjab050

Cite this

@article{4242b301387e41a684f12e4963a00869,

title = "Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy",

abstract = "Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.",

keywords = "Precision medicine, disease outcome, disease prognosis, inflammatory bowel diseases, personalised medicine, response to therapy",

author = "Bram Verstockt and Noor, \{Nurulamin M.\} and Marigorta, \{Urko M.\} and Polychronis Pavlidis and Parakkal Deepak and Ungaro, \{Ryan C.\} and Claudio Fiocchi and Joana Torres and Michael Scharl",

year = "2021",

month = sep,

day = "1",

doi = "10.1093/ecco-jcc/jjab050",

language = "English",

volume = "15",

pages = "1431--1442",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Results of the Seventh Scientific Workshop of ECCO

T2 - Precision Medicine in IBD-Disease Outcome and Response to Therapy

AU - Verstockt, Bram

AU - Noor, Nurulamin M.

AU - Marigorta, Urko M.

AU - Pavlidis, Polychronis

AU - Deepak, Parakkal

AU - Ungaro, Ryan C.

AU - Fiocchi, Claudio

AU - Torres, Joana

AU - Scharl, Michael

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.

AB - Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.

KW - Precision medicine

KW - disease outcome

KW - disease prognosis

KW - inflammatory bowel diseases

KW - personalised medicine

KW - response to therapy

UR - https://www.scopus.com/pages/publications/85111948849

U2 - 10.1093/ecco-jcc/jjab050

DO - 10.1093/ecco-jcc/jjab050

M3 - Article

C2 - 33730756

AN - SCOPUS:85111948849

SN - 1873-9946

VL - 15

SP - 1431

EP - 1442

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

IS - 9

ER -

Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this